Answers are grounded in this paper and cite their sources.
Introduction: Biosensors enable rapid, sensitive detection of biological analytes and continuous physiological monitoring, while nanotechnology, flexible electronics, artificial intelligence, and connected medical-device platforms are accelerating decentralized and personalized healthcare. Methodology: A systematic review was conducted using PubMed/MEDLINE, Scopus, Web of Science Core Collection, ScienceDirect, IEEE Xplore, and Google Scholar for literature published from January 2015 to March 2026. The search identified 1,436 database records and 46 additional records; after duplicate removal and screening, 118 studies met the eligibility criteria and were synthesized narratively in accordance with PRISMA 2020. Results: Electrochemical biosensors remained the most widely deployed platform because of affordability and portability, while optical, piezoelectric, field-effect transistor, microfluidic, and nanotechnology-enabled biosensors demonstrated important clinical applications. Wearable biosensors integrated with intelligent analytics and connected-device platforms supported continuous monitoring and predictive alerts. Graphene-based sensors, CRISPR-assisted diagnostics, and implantable biosensors showed strong potential for precision medicine. Conclusion: Clinical translation remains limited by biofouling, manufacturing cost, regulatory complexity, cybersecurity, and inadequate implementation in resource-constrained settings. Future research should prioritize affordability, regulatory harmonization, robust validation, and equitable deployment, particularly in low- and middle-income countries.
No takes yet. Share an insight, caveat, or question.
Debekeme et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: